The Anti-Cancer Effect of Four Curcumin Analogues on Human Glioma Cells
Siou-Min Luo,Yi-Ping Wu,Li-Chun Huang,Shih-Ming Huang,Dueng-Yuan Hueng
DOI: https://doi.org/10.2147/OTT.S313961
IF: 4
2021-08-04
OncoTargets and Therapy
Abstract:Siou-Min Luo, 1 Yi-Ping Wu, 2 Li-Chun Huang, 2 Shih-Ming Huang, 1, 2 Dueng-Yuan Hueng 1– 3 1 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China; 2 Department of Biochemistry, National Defense Medical Center, Taipei, Taiwan, Republic of China; 3 Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China Correspondence: Dueng-Yuan Hueng Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China Tel +886-2-8792-3100 #18802 Email Purpose: Glioblastoma multiforme (GBM) is the primary aggressive malignancy of the brain with poor outcome. Curcumin analogues are polyphenolic compounds as the bioactive substances extracted from turmeric. This study aims to investigate the anti-cancer effects of four curcumin analogues. Furthermore, the molecular mechanisms of dimethoxycurcumin in human gliomas were analyzed by Western blot. Materials and Methods: Human LN229 and GBM8401 glioma cells were treated by four curcumin analogues with different number of methoxy groups. The cell viability, cell cycle, apoptosis, proliferation and ROS production of human gliomas were analyzed by flow cytometry. Moreover, the effects of four curcumin analogues on tumorigenesis of gliomas were conducted by wound healing assay and colony formation assay. Furthermore, the molecular mechanisms of dimethoxycurcumin in human gliomas were analyzed by Western blot. Results: Our data showed that four different curcumin analogues including curcumin, bisdemethoxycurcumin, demethoxycurcumin, and dimethoxycurcumin promote sub-G1 phase, G2/M arrest, apoptosis, and ROS production in human glioma cells. Moreover, dimethoxycurcumin suppressed cell viability, migration, and colony formation, induction of sub-G1, G2/M arrest, apoptosis, and ROS production in glioma cells. Moreover, the mechanism of dimethoxycurcumin is ROS production to increase LC3B-II expression to induce autophagy. Furthermore, dimethoxycurcumin suppressed apoptotic marker, BCL-2 to promote apoptosis in LN229 and GBM8401 glioma cells. Conclusion: Our study found that dimethoxycurcumin induced apoptosis, autophagy, ROS production and suppressed cell viability in human gliomas. Dimethoxycurcumin might be a potential therapeutic candidate in human glioma cells. Keywords: curcumin, bisdemethoxycurcumin, demethoxycurcumin, dimethoxycurcumin, glioblastoma Glioblastoma multiforme (GBM) is the primary aggressive malignancy of the brain. Current standard treatment includes concurrent chemoradiotherapy after surgical resection methods have been the treatments. 1 Since the cell biology of human glioma possesses invasiveness, angiogenesis, and high proliferation leading to poor survival. 2 , 3 Therefore, the study of a new compound to improve cell biology in patients with glioblastomas is mandatory. Curcuminoids have many pharmacological activities used in Ayurvedic and Chinese medicine for centuries. 4 Curcumin can pass through the blood-brain barrier (BBB) and is detectable in cerebrospinal fluid of mouse model. 5 Curcumin, which is reported to target several signaling pathways mediated by p53, Ras, PI3K, and AKT in breast cancer. 6 Curcumin induced G2/M phase arrest and suppresses Wnt/β-catenin signaling pathway to reduce cell proliferation in medulloblastoma. 7 Curcuminoids belong to polyphenolic compounds containing about 77% pure curcumin (Cur), 17% demethoxycurcumin (DMC) and 3% bisdemethoxycurcumin (BisDMC). Curcuminoids are bioactive substances extracted from turmeric (Curcuma longa Linn). 8 A previous study reported that demethoxycurcumin increases lung cancer cell DNA damage to reduce DNA repair-related proteins. 9 Demethoxycurcumin suppresses NF-κB pathways to inhibit migration and invasion in HeLa cells. 10 Bisdemethoxycurcumin inhibits PI3K/AKT signaling to sensitize chemotherapy in cisplatin-resistant lung cancer cells. 11 Bisdemethoxycurcumin inhibits ovarian cancer cell through MMPs expressions to reduce oxidative stress. 12 Bisdemethoxycurcumin inactive AKT to inhibit the proliferation of hepatocellular carcinoma through CYLD-mediated deubiquitination. 13 Curcumin, demethoxycurcumin, and bi -Abstract Truncated-
oncology,biotechnology & applied microbiology